News

PBS NewsHour’s Susan Dentzer to speak at CRN conference

BY Michael Johnsen

WASHINGTON — The Council for Responsible Nutrition on Wednesday announced that Susan Dentzer, health analyst at PBS NewsHour and senior policy adviser at the Robert Wood Johnson Foundation, will speak during the closing “Breakfast With…” session at The Conference: CRN’s Annual Symposium for the Dietary Supplement Industry Nov. 5-8.
 
Dentzer will provide analysis on the current state of health care, drawing on her experience reporting on every public and private healthcare trend in recent memory to present, as well as a complete and concise picture of where we have been, where we are headed and the role of the dietary supplement and functional food industry in today’s landscape. Dentzer is an elected member of the Institute of Medicine, as well as a public trustee of the American Board of Medical Specialties and a member of the board of directors of Research!America.
 
“We’re excited to have Ms. Dentzer with us for the final session at The Conference, where, over breakfast, attendees will hear a provocative and forward-looking discussion of the current state of health care with insights they can take home and make a difference with,” said Steve Mister, CRN president and CEO. “We know there are health benefits and cost savings from dietary supplements that are yet to be realized by many U.S. populations at risk for disease, especially among those over 55 years old. The dietary supplement industry has so much to offer and Ms. Dentzer will help spark ideas for potential opportunities.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

CamelBak debuts self-sealing mug

BY Ryan Chavis

PETALUMA, Calif. — CamelBak, manufacturer of personal hydration gear, introduced Forge, a travel mug with a self-sealing, leak-proof cap that aims to bring the in-home coffee experience anywhere. CamelBak is bringing the product to market after realizing consumer demand for improvement in the travel mug space, the company said. 
 
“At CamelBak, we are continuously innovating products, and that’s exactly what we did with Forge,” said Jon Austen, senior director of product management at CamelBak. “We realized the need for an all-in-one, premium travel mug that reinvents how people enjoy coffee and tea on-the-go. Forge offers an innovative drink interface, aroma enhancing design and easy cleaning for superior ease and enjoyment.”
 
CamelBak Forge is the first travel mug with a self-sealing cap and lock-open combo, according to the company. Forge also features a finger loop to carry travel mugs and is optimized for cup holders. 
 
Forge, available beginning this month, comes in a variety of colors and is available in two sizes: 16 oz ($30) and 12 oz ($29). 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA approves updated label for Pfizer’s Embeda

BY Ryan Chavis

NEW YORK — Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 
 
The revised label states that the drug has properties expected to curb abuse via oral and intranasal routes when crushed, though abuse of the drug is still possible. The updated label also incorporates data from a human abuse potential study of intravenous (IV) morphine and naltrexone to simulate crushed Embeda, the company stated. 
 
Embeda is indicated for treatment for pain that is severe enough to require daily, long-term opioid treatment when alternative treatment plans have proven inadequate. Pfizer said it expects the drug to be available in the United States in early 2015.
 
 
“Prescription opioids are an important treatment option for people with chronic pain. However, misuse and abuse of opioids in the U.S. is a serious societal concern, which is why the development of abuse-deterrent formulations of these medicines is a high priority,” said Bob Twillman, Ph.D.,director of policy and advocacy, American Academy of Pain Management. “All opioid medications, including morphine products, have the potential for abuse. We believe that anything that can be done to reduce this risk is a significant development for healthcare providers and their patients.”
 
From 1999 to 2010, the number of fatal overdoses involving prescription painkillers quadrupled, with more than 16,000 deaths in 2010, according to the Centers for Disease Control and Prevention. In 2012, the National Survey on Drug Use and Health showed that more than 12 million people in the United States used prescription painkillers for non-medical purposes in the previous year. Seventy percent of those using non-medical prescription opioids got them from a friend or relative. 
 
“More than one-third of extended-release opioids prescribed are morphine, and Embeda is the first extended-release morphine with the potential to reduce abuse via the oral and intranasal routes when crushed,” said Dr. Steven Romano, SVP and head, Medicines Development Group, Pfizer Global Innovative Pharmaceutical Business. “Pfizer believes that abuse-deterrent products like Embeda are important to help address the growing public health problem of opioid abuse in the U.S.”
 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?